These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

421 related articles for article (PubMed ID: 32415802)

  • 1. The effects of canagliflozin compared to sitagliptin on cardiorespiratory fitness in type 2 diabetes mellitus and heart failure with reduced ejection fraction: The CANA-HF study.
    Carbone S; Billingsley HE; Canada JM; Bressi E; Rotelli B; Kadariya D; Dixon DL; Markley R; Trankle CR; Cooke R; Rao K; B Shah K; Medina de Chazal H; Chiabrando JG; Vecchié A; Dell M; L Mihalick V; Bogaev R; Hart L; Van Tassell BW; Arena R; Celi FS; Abbate A
    Diabetes Metab Res Rev; 2020 Nov; 36(8):e3335. PubMed ID: 32415802
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Effect of Canagliflozin Compared With Sitagliptin on Serum Lipids in Patients with Type 2 Diabetes Mellitus and Heart Failure with Reduced Ejection Fraction: A Post-Hoc Analysis of the CANA-HF Study.
    Dixon DL; Billingsley HE; Canada JM; Trankle CR; Kadariya D; Cooke R; Hart L; Van Tassell B; Abbate A; Carbone S
    J Cardiovasc Pharmacol; 2021 Sep; 78(3):407-410. PubMed ID: 34132690
    [TBL] [Abstract][Full Text] [Related]  

  • 3. IL-1 Blockade in Patients With Heart Failure With Preserved Ejection Fraction.
    Van Tassell BW; Trankle CR; Canada JM; Carbone S; Buckley L; Kadariya D; Del Buono MG; Billingsley H; Wohlford G; Viscusi M; Oddi-Erdle C; Abouzaki NA; Dixon D; Biondi-Zoccai G; Arena R; Abbate A
    Circ Heart Fail; 2018 Aug; 11(8):e005036. PubMed ID: 30354558
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Prognostic Value of Cardiopulmonary Exercise Testing in Heart Failure With Reduced, Midrange, and Preserved Ejection Fraction.
    Nadruz W; West E; Sengeløv M; Santos M; Groarke JD; Forman DE; Claggett B; Skali H; Shah AM
    J Am Heart Assoc; 2017 Oct; 6(11):. PubMed ID: 29089342
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Effects of empagliflozin on cardiorespiratory fitness and significant interaction of loop diuretics.
    Carbone S; Canada JM; Billingsley HE; Kadariya D; Dixon DL; Trankle CR; Buckley LF; Markley R; Vo C; Medina de Chazal H; Christopher S; Buzzetti R; Van Tassell BW; Abbate A
    Diabetes Obes Metab; 2018 Aug; 20(8):2014-2018. PubMed ID: 29603546
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Real-world evaluation of glycemic control among patients with type 2 diabetes mellitus treated with canagliflozin versus dipeptidyl peptidase-4 inhibitors.
    Thayer S; Chow W; Korrer S; Aguilar R
    Curr Med Res Opin; 2016 Jun; 32(6):1087-96. PubMed ID: 26938635
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Effect of canagliflozin on N-terminal pro-brain natriuretic peptide in patients with type 2 diabetes and chronic heart failure according to baseline use of glucose-lowering agents.
    Tanaka A; Toyoda S; Imai T; Shiina K; Tomiyama H; Matsuzawa Y; Okumura T; Kanzaki Y; Onishi K; Kiyosue A; Nishino M; Sakata Y; Node K;
    Cardiovasc Diabetol; 2021 Sep; 20(1):175. PubMed ID: 34479543
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Cost-effectiveness of Canagliflozin versus Sitagliptin When Added to Metformin and Sulfonylurea in Type 2 Diabetes in Canada.
    Sabapathy S; Neslusan C; Yoong K; Teschemaker A; Johansen P; Willis M
    J Popul Ther Clin Pharmacol; 2016; 23(2):e151-68. PubMed ID: 27463416
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Empagliflozin improves cardiorespiratory fitness in type 2 diabetes: translational implications.
    Kumar N; Garg A; Bhatt DL; Sabongui S; Gupta N; Chaudhry S; Arena R; Verma S
    Can J Physiol Pharmacol; 2018 Nov; 96(11):1184-1187. PubMed ID: 30265814
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Effects of sitagliptin on exercise capacity and hemodynamics in patients with type 2 diabetes mellitus and coronary artery disease.
    Fujimoto N; Moriwaki K; Takeuchi T; Sawai T; Sato Y; Kumagai N; Masuda J; Nakamori S; Ito M; Dohi K
    Heart Vessels; 2020 May; 35(5):605-613. PubMed ID: 31641887
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Empagliflozin and the Risk of Heart Failure Hospitalization in Routine Clinical Care.
    Patorno E; Pawar A; Franklin JM; Najafzadeh M; Déruaz-Luyet A; Brodovicz KG; Sambevski S; Bessette LG; Santiago Ortiz AJ; Kulldorff M; Schneeweiss S
    Circulation; 2019 Jun; 139(25):2822-2830. PubMed ID: 30955357
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Peak VO2 and VE/VCO2 slope in betablockers era in patients with heart failure: a Brazilian experience.
    Guimarães GV; Silva MS; d'Avila VM; Ferreira SM; Silva CP; Bocchi EA
    Arq Bras Cardiol; 2008 Jul; 91(1):39-48. PubMed ID: 18660944
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Sitagliptin improves diastolic cardiac function but not cardiorespiratory fitness in adults with type 2 diabetes.
    Scalzo RL; Rafferty D; Schauer I; Huebschmann AG; Cree-Green M; Reusch JEB; Regensteiner JG
    J Diabetes Complications; 2019 Aug; 33(8):561-566. PubMed ID: 31182338
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Sodium-glucose cotransporter 2 inhibitors vs. sitagliptin in heart failure and type 2 diabetes: an observational cohort study.
    Fu EL; Patorno E; Everett BM; Vaduganathan M; Solomon SD; Levin R; Schneeweiss S; Desai RJ
    Eur Heart J; 2023 Jun; 44(24):2216-2230. PubMed ID: 37259575
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Insulin ameliorates exercise ventilatory efficiency and oxygen uptake in patients with heart failure-type 2 diabetes comorbidity.
    Guazzi M; Tumminello G; Matturri M; Guazzi MD
    J Am Coll Cardiol; 2003 Sep; 42(6):1044-50. PubMed ID: 13678928
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A flattening oxygen consumption trajectory phenotypes disease severity and poor prognosis in patients with heart failure with reduced, mid-range, and preserved ejection fraction.
    Popovic D; Arena R; Guazzi M
    Eur J Heart Fail; 2018 Jul; 20(7):1115-1124. PubMed ID: 29405511
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Heart failure prognosis over time: how the prognostic role of oxygen consumption and ventilatory efficiency during exercise has changed in the last 20 years.
    Paolillo S; Veglia F; Salvioni E; Corrà U; Piepoli M; Lagioia R; Limongelli G; Sinagra G; Cattadori G; Scardovi AB; Metra M; Senni M; Bonomi A; Scrutinio D; Raimondo R; Emdin M; Magrì D; Parati G; Re F; Cicoira M; Minà C; Correale M; Frigerio M; Bussotti M; Battaia E; Guazzi M; Badagliacca R; Di Lenarda A; Maggioni A; Passino C; Sciomer S; Pacileo G; Mapelli M; Vignati C; Clemenza F; Binno S; Lombardi C; Filardi PP; Agostoni P;
    Eur J Heart Fail; 2019 Feb; 21(2):208-217. PubMed ID: 30632680
    [TBL] [Abstract][Full Text] [Related]  

  • 18. European Society of Cardiology/Heart Failure Association position paper on the role and safety of new glucose-lowering drugs in patients with heart failure.
    Seferović PM; Coats AJS; Ponikowski P; Filippatos G; Huelsmann M; Jhund PS; Polovina MM; Komajda M; Seferović J; Sari I; Cosentino F; Ambrosio G; Metra M; Piepoli M; Chioncel O; Lund LH; Thum T; De Boer RA; Mullens W; Lopatin Y; Volterrani M; Hill L; Bauersachs J; Lyon A; Petrie MC; Anker S; Rosano GMC
    Eur J Heart Fail; 2020 Feb; 22(2):196-213. PubMed ID: 31816162
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Rate-Adaptive Atrial Pacing for Heart Failure With Preserved Ejection Fraction: The RAPID-HF Randomized Clinical Trial.
    Reddy YNV; Koepp KE; Carter R; Win S; Jain CC; Olson TP; Johnson BD; Rea R; Redfield MM; Borlaug BA
    JAMA; 2023 Mar; 329(10):801-809. PubMed ID: 36871285
    [TBL] [Abstract][Full Text] [Related]  

  • 20. SODIUM GLUCOSE COTRANSPORTER 2 AND DIPEPTIDYL PEPTIDASE-4 INHIBITION: PROMISE OF A DYNAMIC DUO.
    Lingvay I
    Endocr Pract; 2017 Jul; 23(7):831-840. PubMed ID: 28332871
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 22.